TriSalus Life Sciences, Inc. — Earnings Quality Grade C
TLSI · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 53 days, change -10 days YoY
AR growth 28.9% vs revenue growth 53.4%
Revenue 53.4%, CFFO 55.9%. Cash follows revenue
Expense Quality
Inventory -24.0% vs COGS 69.8%. Normal
CapEx growth 166.1% is >2x revenue growth 53.4%
SG&A/Gross Profit = 131.4%, exceeds 70%
Gross margin 84.6%, change -1.5pp. Stable
Cash Flow Quality
CFFO/NI = 0.46. Below 1.0
FCF is negative ($-0.0B)
Accruals ratio = -60.0%. Low accruals
Cash $0.0B covers 59% of debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -4.9x (<2x). Financial stress
Other assets -1.2% vs revenue 53.4%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
No goodwill
Manipulation Score
M-Score = -5.01 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor TLSI continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25